Scan to download the Future Doctor app
Started AI research and development. Received investment from China Electronics Data and began joint R&D with IBM Watson.
Official launch of the APP.
Company established in Chengdu.
Obtained one of the first batch of internet hospital licenses in China.
Official launch of the internet hospital open platform.
Developed the first domestic AI early screening model for multiple sclerosis prevention.
The first hepatitis C patient in China and Medlinker to be cured via the internet hospital system was born.
Established the first domestic infectious disease department in an internet hospital.
Began innovating AI algorithms and building AI diagnosis and treatment models.
Pioneered a multi-post operation model in the industry, launching comprehensive disease management.
Launched multiple sets of chronic disease management gold standards and SOPs, and initiated consensus building among multidisciplinary experts.
Became among the first batch of internet hospitals in China (Chengdu, Beijing) to enable online medical insurance payment.
Jointly released China's first expert consensus on the online management of diabetes in internet hospitals.
"Medlinker Connect", China's first digital marketing platform for pharmaceutical enterprises, officially launched.
Held the inaugural AI Medicine Conference and co-founded the 'AI Medicine Committee' with 39 experts.
Held the world’s first live experiment on consistency research between generative AI doctors and real doctors.
Released China's first vertical medical large model, MedGPT.
Awarded Tencent Cloud’s 2024 'Best Trend Leading Enterprise of the Year'; AI products once again recognized by the industry.
Participated as a large model application enterprise in developing the 'Maturity Assessment Model for Large Models in Healthcare'.
Official launch of Future Doctor Expert GPT.
In the medical diagnosis test report by SuperCLUE, a third-party comprehensive Chinese large model evaluation platform, 'Future Doctor' scored 91.67 points, ranking first in the industry.
Launched China's first AI doctor application-level product, 'Future Doctor'.
MedGPT completed real patient testing, achieving an initial diagnostic relevance rate of 84.4%.
'Future Doctor' shortlisted for the 'Prix Galien USA 2025 Best Digital Health Solution Award', known as the Nobel Prize of the pharmaceutical industry.
MedGPT, the self-developed healthcare large model supporting Future Doctor, surpassed OpenAI-o3 in international authoritative evaluations, becoming the world's number one in the field.
'Future Doctor' reached an official cooperation with the People's Health App.
A brand-new version of Future Doctor launched, introducing the 'Expert Free Consultation' service.
'Future Doctor' joined the Xuexi Qiangguo Health Channel, providing free AI online health consultation services.
Formed a strategic partnership with Tencent Cloud to deeply cooperate on computing power support, engineering tools, and compliance frameworks.
Teamed up with Shenzhen Longgang District Community Health Service Management Center to create China's first grassroots general practitioner intelligent agent.
Future Doctor was named one of VBData’s “Top 50 Most Investable Companies in China’s Healthcare Industry” and recognized by QbitAI as one of the “2026 AIGC Products to Watch.”
Future Doctor signed a partnership with TAIKANG LIFE to bring AI-enabled real-doctor consultations and AI-powered chronic disease management services into insurance-based healthcare scenarios.
Future Doctor’s research team published a paper in Nature Portfolio’s npj Digital Medicine, introducing the Clinical Safety-Effectiveness Dual-Track Benchmark (CSEDB) for medical AI. In the evaluation of leading global models, MedGPT ranked first across three core metrics.